PD-L1在ALK阳性非小细胞肺癌中的表达特征及临床意义
Expression Characteristics and Clinical Significance of PD-L1 in ALK-Positive Non-Small Cell Lung Cancer
DOI: 10.12677/acm.2026.162427, PDF,   
作者: 刘达宏：山东大学医学融合与实践中心，山东 济南；山东省立医院呼吸与危重症医学科，山东 济南
关键词: 非小细胞肺癌；ALK；PD-L1表达；分子检测；研究进展；Non-Small Cell Lung Cancer； ALK； PD-L1 Expression； Molecular Detection； Research Progress
摘要: 程序性死亡配体1 (PD-L1)在非小细胞肺癌(non-small cell lung cancer, NSCLC)中的表达已成为预测免疫检查点抑制剂疗效的重要生物标志物。然而，在ALK阳性NSCLC这一特殊分子亚型中，PD-L1 (programmed death ligand 1, PD-L1)的表达特征及其临床意义仍存在较大争议。现有研究显示，ALK阳性NSCLC中的PD-L1表达具有显著异质性，与EGFR突变型NSCLC相比可能呈现不同的表达模式。此外，PD-L1表达水平可能影响ALK抑制剂与免疫治疗的联合疗效，但相关临床证据仍有限。深入阐明PD-L1在ALK阳性NSCLC中的生物学特征，将有助于推动这一患者群体的精准治疗。本文旨在综述ALK阳性NSCLC中PD-L1表达的研究进展，重点探讨其表达水平、检测方法、与临床病理特征的相关性以及对治疗策略的指导价值。
Abstract: Programmed death ligand 1 (PD-L1) expression in non-small cell lung cancer (NSCLC) has become an important biomarker for predicting the efficacy of immune checkpoint inhibitors. However, the expression characteristics of PD-L1 (programmed death ligand 1, PD-L1) and its clinical significance in ALK-positive NSCLC, a specific molecular subtype, are still controversial. Existing studies have shown that PD-L1 expression in ALK-positive NSCLC is characterized by significant heterogeneity and may show a different expression pattern compared with EGFR-mutant NSCLC. In addition, the level of PD-L1 expression may affect the combined efficacy of ALK inhibitors and immunotherapy, but relevant clinical evidence remains limited. In-depth elucidation of the biological characteristics of PD-L1 in ALK-positive NSCLC will help to advance precision therapy in this patient population. The aim of this article is to review the research progress of PD-L1 expression in ALK-positive NSCLC, focusing on its expression level, detection methods, correlation with clinicopathologic features, and guidance value for therapeutic strategies.
文章引用：刘达宏. PD-L1在ALK阳性非小细胞肺癌中的表达特征及临床意义[J]. 临床医学进展, 2026, 16(2): 586-594. https://doi.org/10.12677/acm.2026.162427

参考文献

[1] Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
[2] Thamrongjirapat, T., Muntham, D., Incharoen, P., Trachu, N., Sae-Lim, P., Sarachai, N., et al. (2024) Molecular Alterations and Clinical Prognostic Factors in Resectable Non-Small Cell Lung Cancer. BMC Cancer, 24, Article No. 200. [Google Scholar] [CrossRef] [PubMed]
[3] Nan, X., Xie, C., Yu, X. and Liu, J. (2017) EGFR TKI as First-Line Treatment for Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer. Oncotarget, 8, 75712-75726. [Google Scholar] [CrossRef] [PubMed]
[4] Wang, T., Zhang, L. and Cheng, Y. (2024) Clinical Status and Perspective on the Application of Immunotherapy Combined with Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Review. Chinese Clinical Oncology, 13, Article 26. [Google Scholar] [CrossRef] [PubMed]
[5] Willis, C., Bauer, H., Au, T.H., Menon, J., Unni, S., Tran, D., et al. (2022) Real-World Survival Analysis by Tumor Mutational Burden in Non-Small Cell Lung Cancer: A Multisite U.S. Study. Oncotarget, 13, 257-270. [Google Scholar] [CrossRef] [PubMed]
[6] Felip, E., de Braud, F.G., Maur, M., Loong, H.H., Shaw, A.T., Vansteenkiste, J.F., et al. (2020) Ceritinib Plus Nivolumab in Patients with Advanced Alk-Rearranged Non-Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study. Journal of Thoracic Oncology, 15, 392-403. [Google Scholar] [CrossRef] [PubMed]
[7] Peng, S., Wang, R., Zhang, X., Ma, Y., Zhong, L., Li, K., et al. (2019) EGFR-TKI Resistance Promotes Immune Escape in Lung Cancer via Increased PD-L1 Expression. Molecular Cancer, 18, Article No. 165. [Google Scholar] [CrossRef] [PubMed]
[8] Takeda, M., Kasai, T., Naito, M., Tamiya, A., Taniguchi, Y., Saijo, N., et al. (2019) Programmed Death-Ligand 1 Expression with Clone 22C3 in Non-Small Cell Lung Cancer: A Single Institution Experience. Clinical Medicine Insights: Oncology, 13, Article 1179554918821314.
[9] Garassino, M.C., Cho, B.C., Kim, J.H., Mazières, J., Vansteenkiste, J., Lena, H., et al. (2018) Durvalumab as Third-Line or Later Treatment for Advanced Non-Small-Cell Lung Cancer (ATLANTIC): An Open-Label, Single-Arm, Phase 2 Study. The Lancet Oncology, 19, 521-536. [Google Scholar] [CrossRef] [PubMed]
[10] Song, Z., Yu, X., Cheng, G. and Zhang, Y. (2016) Programmed Death-Ligand 1 Expression Associated with Molecular Characteristics in Surgically Resected Lung Adenocarcinoma. Journal of Translational Medicine, 14, Article No. 188. [Google Scholar] [CrossRef] [PubMed]
[11] Shin, J.E., Park, S., Jung, H.A., Sun, J., Lee, S., Ahn, J.S., et al. (2025) Combination of Chemotherapy and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer with Actionable Gene Alterations Other than EGFR, ALK, and ROS1 Mutations: A Retrospective Observational Study. BMC Cancer, 25, Article No. 1616. [Google Scholar] [CrossRef] 
[12] 王皓, 陈宗友, 刘一雄. PD-L1检测方法及研究进展[J]. 医学诊断, 2022, 12(3): 265-270.
[13] 陈晓童. PD-L1临床免疫组织化学检测新进展[J]. 世界最新医学信息文摘, 2018, 18(17): 21-22.
[14] Hirsch, F.R., McElhinny, A., Stanforth, D., Ranger-Moore, J., Jansson, M., Kulangara, K., et al. (2017) PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project. Journal of Thoracic Oncology, 12, 208-222. [Google Scholar] [CrossRef] [PubMed]
[15] 邢杰, 赵继开, 丁闻洁, 韩昱晨. 免疫组化双重染色技术在胸腺肿瘤PD-L1检测中的应用[J]. 临床与实验病理学杂志, 2020, 36(12): 1482-1484.
[16] Duncan, D.J., Scott, M., Scorer, P. and Barker, C. (2019) Assessment of PD-L1 mRNA and Protein Expression in Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Urothelial Carcinoma Tissue Specimens Using RNAScope and Immunohistochemistry. PLOS ONE, 14, e0215393. [Google Scholar] [CrossRef] [PubMed]
[17] 杨林超, 李文杰, 陈楠. 核医学显像探针在肿瘤PD-L1免疫治疗中的应用[J]. 肿瘤防治研究, 2021, 48(12): 1123-1128.
[18] Chen, M., Wang, Z., Liu, Z., Deng, T., Wang, X., Chang, Z., et al. (2023) PD-1/PD-L1 Inhibitor Plus Chemotherapy versus PD-1/PD-L1 Inhibitor in Microsatellite Instability Gastrointestinal Cancers: A Multicenter Retrospective Study. JCO Precision Oncology, 7, e2200463. [Google Scholar] [CrossRef] [PubMed]
[19] Zhu, J., Zhang, T., Li, J., Lin, J., Liang, W., Huang, W., et al. (2019) Association between Tumor Mutation Burden (TMB) and Outcomes of Cancer Patients Treated with PD-1/PD-L1 Inhibitions: A Meta-Analysis. Frontiers in Pharmacology, 10, Article 673. [Google Scholar] [CrossRef] [PubMed]
[20] Gniadek, T.J., Li, Q.K., Tully, E., Chatterjee, S., Nimmagadda, S. and Gabrielson, E. (2017) Heterogeneous Expression of PD-L1 in Pulmonary Squamous Cell Carcinoma and Adenocarcinoma: Implications for Assessment by Small Biopsy. Modern Pathology, 30, 530-538. [Google Scholar] [CrossRef] [PubMed]
[21] Adams, D.L., Adams, D.K., He, J., Kalhor, N., Zhang, M., Xu, T., et al. (2017) Sequential Tracking of PD-L1 Expression and RAD50 Induction in Circulating Tumor and Stromal Cells of Lung Cancer Patients Undergoing Radiotherapy. Clinical Cancer Research, 23, 5948-5958. [Google Scholar] [CrossRef] [PubMed]
[22] Skov, B.G. and Skov, T. (2017) Paired Comparison of PD-L1 Expression on Cytologic and Histologic Specimens from Malignancies in the Lung Assessed with PD-L1 IHC 28-8pharmDx and PD-L1 IHC 22C3pharmDx. Applied Immunohistochemistry & Molecular Morphology, 25, 453-459. [Google Scholar] [CrossRef] [PubMed]
[23] Sakakibara, R., Inamura, K., Tambo, Y., Ninomiya, H., Kitazono, S., Yanagitani, N., et al. (2017) EBUS-TBNA as a Promising Method for the Evaluation of Tumor PD-L1 Expression in Lung Cancer. Clinical Lung Cancer, 18, 527-534.e1. [Google Scholar] [CrossRef] [PubMed]
[24] Midha, A., Sharpe, A., Scott, M., Walker, J., Shi, K., Ballas, M., et al. (2016) PD-L1 Expression in Advanced NSCLC: Primary Lesions versus Metastatic Sites and Impact of Sample Age. Journal of Clinical Oncology, 34, 3025-3025. [Google Scholar] [CrossRef] 
[25] Tan, Q., Ji, Y., Wang, X.L., Wang, Z.W., Qi, X.W. and Liu, Y.K. (2023) Clinicopathological Features of Patients with Ret Fusion-Positive Non-Small Cell Lung Cancer. Chinese Journal of Pathology, 52, 124-128.
[26] Wang, L., Kong, Y., Zhang, Y. and Mu, C. (2024) The Impact of PD-L1 Expression Status on the Prognosis of ALK-Positive Lung Cancer Patients. Cancer Treatment and Research Communications, 42, Article 100868. [Google Scholar] [CrossRef] [PubMed]
[27] Chang, G.C., Yang, T.Y., Chen, K.C., Hsu, K.H., Huang, Y.H., Su, K.Y., et al. (2020) ALK Variants, PD-L1 Expression, and Their Association with Outcomes in ALK-Positive NSCLC Patients. Scientific Reports, 10, Article No. 21063. [Google Scholar] [CrossRef] [PubMed]
[28] Schneider, J.L., Lin, J.J. and Shaw, A.T. (2023) ALK-Positive Lung Cancer: A Moving Target. Nature Cancer, 4, 330-343. [Google Scholar] [CrossRef] [PubMed]
[29] Hanna, N.H., Schneider, B.J., Temin, S., Baker Jr, S., Brahmer, J., Ellis, P.M., et al. (2020) Therapy for Stage IV Non-Small-Cell Lung Cancer without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update. Journal of Clinical Oncology, 38, 1608-1632.
[30] Katayama, Y., Yamada, T., Tanimura, K., Tokuda, S., Morimoto, K., Hirai, S., et al. (2023) Adaptive Resistance to Lorlatinib via EGFR Signaling in ALK-Rearranged Lung Cancer. npj Precision Oncology, 7, Article No. 12. [Google Scholar] [CrossRef] [PubMed]
[31] Zhang, B., Zeng, J., Zhang, H., Zhu, S., Wang, H., He, J., et al. (2022) Characteristics of the Immune Microenvironment and Their Clinical Significance in Non-Small Cell Lung Cancer Patients with ALK-Rearranged Mutation. Frontiers in Immunology, 13, Article 974581. [Google Scholar] [CrossRef] [PubMed]
[32] Bylicki, O., Tomasini, P., Radj, G., Guisier, F., Monnet, I., Ricordel, C., et al. (2023) Atezolizumab with or without Bevacizumab and Platinum-Pemetrexed in Patients with Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer with EGFR Mutation, ALK Rearrangement or ROS1 Fusion Progressing after Targeted Therapies: A Multicentre Phase II Open-Label Non-Randomised Study GFPC 06-2018. European Journal of Cancer, 183, 38-48. [Google Scholar] [CrossRef] [PubMed]
[33] Shiraishi, Y., Kishimoto, J., Sugawara, S., Mizutani, H., Daga, H., Azuma, K., et al. (2024) Atezolizumab and Platinum Plus Pemetrexed with or without Bevacizumab for Metastatic Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncology, 10, 315-324. [Google Scholar] [CrossRef] [PubMed]
[34] Lin, Q.X., Song, W.W., Xie, W.X., Deng, Y.T., Gong, Y.N., Liu, Y.R., et al. (2025) Sequential Treatment of Anti-PD-L1 Therapy Prior to Anti-VEGFR2 Therapy Contributes to More Significant Clinical Benefits in Non-Small Cell Lung Cancer. Neoplasia, 59, 101077. [Google Scholar] [CrossRef] [PubMed]
[35] Socinski, M.A., Jotte, R.M., Cappuzzo, F., Nishio, M., Mok, T.S.K., Reck, M., et al. (2023) Association of Immune-Related Adverse Events with Efficacy of Atezolizumab in Patients with Non-Small Cell Lung Cancer: Pooled Analyses of the Phase 3 IMpower130, IMpower132, and IMpower150 Randomized Clinical Trials. JAMA Oncology, 9, 527-535.
[36] Zhao, S., Zhou, H., Yang, N., Wang, Z., Jin, W., Ma, Y., et al. (2025) Safety, Efficacy, and Biomarker Analysis of Deulorlatinib (TGRX-326) in Anaplastic Lymphoma Kinase-Positive NSCLC: A Multicenter, Open-Label, Phase 1/1b Trial. Journal of Thoracic Oncology, 20, 750-762. [Google Scholar] [CrossRef] [PubMed]
[37] Zhang, H., Xia, W., Zhang, Y., Bao, S., Zeng, J., Li, X., et al. (2025) Ensartinib as a Neoadjuvant Therapy for Stage IIIA Non-Small Cell Lung Cancer Patients with EML4-ALK Fusion: A Case Report and Literature Review. Frontiers in Oncology, 15, Article 1474997. [Google Scholar] [CrossRef] [PubMed]
[38] Fan, J. and Zhang, T. (2024) Multi-Index Comprehensive Evaluation of the Efficacy and Response Mechanism of Immunotherapy in Non-Small Cell Lung Cancer. Clinical and Translational Oncology, 26, 3124-3130. [Google Scholar] [CrossRef] [PubMed]
[39] Franz, L., Alessandrini, L., Calvanese, L., Crosetta, G., Frigo, A.C. and Marioni, G. (2021) Angiogenesis, Programmed Death Ligand 1 (PD-L1) and Immune Microenvironment Association in Laryngeal Carcinoma. Pathology, 53, 844-851. [Google Scholar] [CrossRef] [PubMed]

为你推荐